Abstract
Although ibuprofen is one of the most widely used nonsteroidal anti-inflammatory drugs (NSAIDs), it exhibits poor solubility in aqueous and physiological environments as a free acid. In order to improve its oral bioavailability and rate of uptake, extensive research into the development of new formulations of ibuprofen has been undertaken, including the use of excipients as well as ibuprofen salts, such as ibuprofen lysinate and ibuprofen, sodium salt. The ultimate goals of these studies are to reduce the time required for maximum uptake of ibuprofen, as this period of time is directly proportional to the rate of onset of analgesic/anti-inflammatory effects, and to increase the half-life of the drug within the body; that is, the duration of action of the effects of the drug. Herein, we present a pharmaceutical cocrystal of ibuprofen and the biocompatible metal-organic framework called CD-MOF. This metal-organic framework (MOF) is based upon γ-cyclodextrin (γ-CD) tori that are coordinated to alkali metal cations (e.g., K+ ions) on both their primary and secondary faces in an alternating manner to form a porous framework built up from (γ-CD)6 cubes. We show that ibuprofen can be incorporated within CD-MOF-1 either by (i) a crystallization process using the potassium salt of ibuprofen as the alkali cation source for production of the MOF or by (ii) absorption and deprotonation of the free-acid, leading to an uptake of 23-26 wt % of ibuprofen within the CD-MOF. In vitro viability studies revealed that the CD-MOF is inherently not affecting the viability of the cells with no IC50 value determined up to a concentration of 100 μM. Bioavailability investigations were conducted on mice, and the ibuprofen/CD-MOF pharmaceutical cocrystal was compared to control samples of the potassium salt of ibuprofen in the presence and absence of γ-CD. From these animal studies, we observed that the ibuprofen/CD-MOF-1 cocrystal exhibits the same rapid uptake of ibuprofen as the ibuprofen potassium salt control sample with a peak plasma concentration observed within 20 min, and the cocrystal has the added benefit of a 100% longer half-life in blood plasma samples and is intrinsically less hygroscopic than the pure salt form.
Original language | English (US) |
---|---|
Pages (from-to) | 1831-1839 |
Number of pages | 9 |
Journal | Molecular Pharmaceutics |
Volume | 14 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2017 |
Funding
This research is part of the Joint Center of Excellence in Integrated Nano-Systems (JCIN) at King Abdulaziz City for Science and Technology (KACST) and Northwestern University (NU). The authors would like to thank both KACST and NU for their continued support of this research. This work was supported by the services of the Developmental Therapeutics Core (DTC) of NU. DTC is supported by Cancer Center Support Grant P30 CA060553 from the National Cancer Institute awarded to the Robert H. Lurie Comprehensive Cancer Center. This work was supported by the Northwestern University Keck Biophysics Facility.
Keywords
- cyclodextrin
- drug delivery
- ibuprofen
- metal−organic framework
ASJC Scopus subject areas
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Encapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies'. Together they form a unique fingerprint.Datasets
-
CCDC 1520334: Experimental Crystal Structure Determination
Hartlieb, K. J. (Creator), Ferris, D. P. (Creator), Holcroft, J. M. (Creator), Kandela, I. (Creator), Stern, C. L. (Creator), Nassar, M. S. (Creator), Botros, Y. Y. (Creator) & Stoddart, J. F. (Creator), Cambridge Crystallographic Data Centre, 2017
DOI: 10.5517/ccdc.csd.cc1n111s, http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc1n111s&sid=DataCite
Dataset